Investors Asset Management of Georgia’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.68M Sell
18,592
-40
-0.2% -$8.61K 1.63% 13
2026
Q1
$4.05M Buy
18,632
+63
+0.3% +$14K 1.66% 14
2025
Q4
$4.24M Buy
18,569
+95
+0.5% +$21.6K 1.75% 13
2025
Q3
$4.28M Sell
18,474
-147
-0.8% -$29.9K 1.82% 11
2025
Q2
$3.46M Buy
18,621
+1,749
+10% +$325K 1.6% 11
2025
Q1
$3.54M Sell
16,872
-490
-3% -$95.3K 1.79% 12
2024
Q4
$3.09M Sell
17,362
-242
-1% -$44.5K 1.5% 14
2024
Q3
$3.48M Sell
17,604
-342
-2% -$63.8K 1.64% 14
2024
Q2
$3.08M Sell
17,946
-82
-0.5% -$13.6K 1.5% 15
2024
Q1
$3.28M Sell
18,028
-170
-0.9% -$29.3K 1.54% 15
2023
Q4
$2.82M Sell
18,198
-140
-0.8% -$20.4K 1.43% 15
2023
Q3
$2.7M Buy
18,338
+260
+1% +$38.2K 1.49% 13
2023
Q2
$2.44M Sell
18,078
-1,480
-8% -$217K 1.26% 15
2023
Q1
$3.12M Buy
19,558
+75
+0.4% +$11.5K 1.66% 12
2022
Q4
$3.15M Sell
19,483
-233
-1% -$35.7K 1.64% 13
2022
Q3
$2.65M Buy
19,716
+505
+3% +$72.5K 1.36% 14
2022
Q2
$2.94M Sell
19,211
-355
-2% -$54.2K 1.53% 13
2022
Q1
$3.17M Buy
19,566
+75
+0.4% +$10.9K 1.6% 11
2021
Q4
$2.64M Sell
19,491
-80
-0.4% -$9.45K 1.26% 14
2021
Q3
$2.11M Buy
19,571
+1,945
+11% +$222K 1.1% 17
2021
Q2
$1.99M Sell
17,626
-50
-0.3% -$5.63K 1.07% 18
2021
Q1
$1.91M Buy
17,676
+365
+2% +$39K 1.11% 19
2020
Q4
$1.85M Sell
17,311
-475
-3% -$45.6K 1.25% 16
2020
Q3
$1.56M Buy
17,786
+50
+0.3% +$4.71K 1.04% 20
2020
Q2
$1.74M Sell
17,736
-313
-2% -$27.6K 1.21% 12
2020
Q1
$1.38M Buy
18,049
+1,050
+6% +$89.4K 1.12% 20
2019
Q4
$1.5M Sell
16,999
-450
-3% -$37.4K 0.91% 26
2019
Q3
$1.32M Buy
17,449
+150
+0.9% +$10.3K 0.84% 28
2019
Q2
$1.26M Buy
17,299
+6,823
+65% +$536K 0.85% 27
2019
Q1
$844K Buy
10,476
+60
+0.6% +$4.91K 0.59% 44
2018
Q4
$960K Sell
10,416
-315
-3% -$27.7K 0.78% 29
2018
Q3
$1.01M Buy
10,731
+100
+0.9% +$9.48K 0.71% 37
2018
Q2
$985K Buy
10,631
+564
+6% +$55.1K 0.72% 39
2018
Q1
$953K Sell
10,067
-250
-2% -$27.5K 0.71% 38
2017
Q4
$998K Sell
10,317
-1,103
-10% -$104K 0.71% 38
2017
Q3
$1.01M Buy
11,420
+525
+5% +$40K 0.75% 34
2017
Q2
$790K Buy
10,895
+100
+0.9% +$6.72K 0.54% 43
2017
Q1
$703K Buy
10,795
+325
+3% +$20.4K 0.49% 49
2016
Q4
$656K Buy
10,470
+660
+7% +$40.3K 0.49% 51
2016
Q3
$619K Hold
9,810
0.47% 51
2016
Q2
$607K Buy
9,810
+800
+9% +$48.7K 0.47% 47
2016
Q1
$515K Buy
9,010
+830
+10% +$46.3K 0.43% 53
2015
Q4
$485K Buy
8,180
+2,810
+52% +$162K 0.41% 54
2015
Q3
$292K Buy
5,370
+370
+7% +$24.1K 0.26% 90
2015
Q2
$336K Buy
5,000
+530
+12% +$34.6K 0.29% 82
2015
Q1
$262K Hold
4,470
0.22% 102
2014
Q4
$293K Buy
+4,470
New +$282K 0.25% 95

Other funds holding ABBV

Investors Asset Management of Georgia's ABBV Position: Q2 2026 in Review

Investors Asset Management of Georgia reduced its AbbVie (ABBV) stake by 0.21% in Q2 2026, selling an estimated $8.61K and leaving 18,592 shares worth $4.68M. The position accounts for 1.63% of the portfolio, ranked #13.

Investors Asset Management of Georgia first reported a position in ABBV in Q4 2014 and has held it in 47 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Investors Asset Management of Georgia held 18,592 shares of AbbVie worth $4.68M as of Q2 2026.
  • Investors Asset Management of Georgia sold 40 AbbVie shares in Q2 2026, an estimated $8.61K.
  • AbbVie made up 1.63% of Investors Asset Management of Georgia's portfolio in Q2 2026, its #13 holding.
  • Investors Asset Management of Georgia first reported a position in AbbVie in Q4 2014 and has held it in 47 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Investors Asset Management of Georgia's 13F filing for Q2 2026, filed 22 Jul 2026.